Please provide your email address to receive an email when new articles are posted on . Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Finerenone could modify chronic kidney ...

Among individuals aged 50 years or younger who experienced an initial myocardial infarction (MI), those with type 2 MI had significantly higher long-term all-cause and cardiovascular mortality ...

In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years. For type 2 diabetes patients older than 50 ...

CV-hypertension-diabetes_G_970433292 Albiglutide is available in other countries, and this trial may serve as an impetus for its reintroduction in the United States, particularly if follow-up results ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.

Sulfonylureas are an older class of type 2 diabetes therapy but remain the most commonly prescribed antidiabetic drug after metformin. Patients taking metformin for type 2 diabetes (T2D) who switch to ...